{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:06:36Z","timestamp":1790024796541,"version":"4.0.1"},"reference-count":120,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Modern immunotherapy together with targeted therapy has revolutionized the treatment of advanced melanoma. Inhibition of immune checkpoints significantly improved the median overall survival and gave hope to many melanoma patients. However, this treatment has three serious drawbacks: high cost, serious side effects, and an effectiveness limited only to approximately 50% of patients. Some patients do not derive any or short-term benefit from this treatment due to primary or secondary resistance. The response to immunotherapy depends on many factors that fall into three main categories: those associated with melanoma cells, those linked to a tumor and its microenvironment, and those classified as individual ontogenic and physiological features of the patient. The first category comprises expression of PD-L1 and HLA proteins on melanoma cells as well as genetic\/genomic metrics such as mutational load, (de)activation of specific signaling pathways and epigenetic factors. The second category is the inflammatory status of the tumor: \u201chot\u201d versus \u201ccold\u201d (i.e., high versus low infiltration of immune cells). The third category comprises metabolome and single nucleotide polymorphisms of specific genes. Here we present up-to-date data on those biological factors influencing melanoma response to immunotherapy with a special focus on signaling pathways regulating the complex process of anti-tumor immune response. We also discuss their potential predictive capacity.<\/jats:p>","DOI":"10.3390\/ijms21114071","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T05:16:14Z","timestamp":1591679774000},"page":"4071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"21","author":[{"given":"Magdalena","family":"Olbryt","sequence":"first","affiliation":[{"name":"Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3975-1309","authenticated-orcid":false,"given":"Marcin","family":"Rajczykowski","sequence":"additional","affiliation":[{"name":"Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-9414","authenticated-orcid":false,"given":"Wies\u0142awa","family":"Wid\u0142ak","sequence":"additional","affiliation":[{"name":"Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1189\/jlb.5RI0116-013RR","article-title":"Combinatorial approach to cancer immunotherapy: Strength in numbers","volume":"100","author":"Vilgelm","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pelster, M.S., and Amaria, R.N. (2020). Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Curr. Treat. Option., 21.","DOI":"10.1007\/s11864-020-0700-z"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13555-019-0292-3","article-title":"Beyond PD-1 Immunotherapy in Malignant Melanoma","volume":"9","author":"Kwiatkowska","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: The impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur. J. Cancer."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Da, L.J., Teng, Y.J., Wang, N., Zaguirre, K., Liu, Y.T., Qi, Y.L., and Song, F.X. (2020). Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. Front. Pharm., 10.","DOI":"10.3389\/fphar.2019.01671"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"New. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to Checkpoint Inhibition in Cancer Immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"OncoTarg. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2018.08.032","article-title":"JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy","volume":"88","author":"Gupta","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Espinosa, E., Marquez-Rodas, I., Soria, A., Berrocal, A., Manzano, J.L., Gonzalez-Cao, M., Martin-Algarra, S., and GEM, S.M.G. (2017). Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). Ann. Transl. Med., 5.","DOI":"10.21037\/atm.2017.08.10"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3390\/cancers7040870","article-title":"Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy","volume":"7","author":"Gallagher","year":"2015","journal-title":"Cancers"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41591-018-0325-y","article-title":"Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma","volume":"25","author":"Trucco","year":"2019","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Shindo, Y., Hazama, S., Tsunedomi, R., Suzuki, N., and Nagano, H. (2019). Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers, 11.","DOI":"10.3390\/cancers11091223"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Samstein, R.M., Lee, C.H., Shoushtari, A.N., Hellmann, M.D., Shen, R., Janjigian, Y.Y., Barron, D.A., Zehir, A., Jordan, E.J., and Omuro, A. (2019). Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet.","DOI":"10.1038\/s41588-018-0312-8"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Miao","year":"2015","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wood, M.A., Weeder, B.R., David, J.K., Nellore, A., and Thompson, R.F. (2020). Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Genome Med., 12.","DOI":"10.1186\/s13073-020-00729-2"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Efremova, M., Finotello, F., Rieder, D., and Trajanoski, Z. (2017). Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01679"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1172\/JCI498","article-title":"beta 2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma","volume":"101","author":"Hicklin","year":"1998","journal-title":"J. Clin. Invest."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade","volume":"175","author":"Shah","year":"2018","journal-title":"Cell"},{"key":"ref_35","first-page":"1336","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/0008-5472.CAN-16-0008","article-title":"Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency","volume":"76","author":"Zhao","year":"2016","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-16-3172","article-title":"Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN gamma Signaling","volume":"77","author":"Donia","year":"2017","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0167-5699(95)80033-6","article-title":"Loss of Hla Class-I Antigens by Melanoma-Cells-Molecular Mechanisms, Functional-Significance and Clinical Relevance","volume":"16","author":"Ferrone","year":"1995","journal-title":"Immunol. Today"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.devcel.2019.06.011","article-title":"DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade","volume":"50","author":"Campbell","year":"2019","journal-title":"Dev. Cell."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-020-14639-9","article-title":"Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma","volume":"11","author":"Kalaora","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e36967","DOI":"10.7554\/eLife.36967","article-title":"Topography of cancer-associated immune cells in human solid tumors","volume":"7","author":"Kather","year":"2018","journal-title":"Elife"},{"key":"ref_45","first-page":"4155","article-title":"Tumor infiltrating lymphocytes: The regulator of melanoma evolution","volume":"17","author":"Antohe","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_46","first-page":"592","article-title":"Tumor infiltrating lymphocytes as a prognostic factor in malignant melanoma. Review of the literature","volume":"22","author":"Gata","year":"2017","journal-title":"J. BUON"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/labinvest.2017.25","article-title":"T-lymphocyte homing: An underappreciated yet critical hurdle for successful cancer immunotherapy","volume":"97","author":"Sackstein","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2017.00233","article-title":"Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review","volume":"7","author":"Jessurun","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"102310","DOI":"10.1016\/j.jaut.2019.102310","article-title":"Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells","volume":"104","author":"Alissafi","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Whelan, M.C., Casey, G., Larkin, J.O., Guinn, B.A., O\u2019Sullivan, G.C., and Tangney, M. (2014). Oral Tolerance to Cancer Can Be Abrogated by T Regulatory Cell Inhibition. PLoS One, 9.","DOI":"10.1371\/journal.pone.0097602"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/iid3.136","article-title":"Transient Treg depletion enhances therapeutic anti-cancer vaccination","volume":"5","author":"Fisher","year":"2017","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13277-015-4315-0","article-title":"Regulatory T cells in the immunotherapy of melanoma","volume":"37","author":"Ouyang","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41467-019-14218-7","article-title":"Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1","volume":"11","author":"Imbert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10453","DOI":"10.1073\/pnas.1819004116","article-title":"TLR1\/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion","volume":"116","author":"Sharma","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/0008-5472.CAN-16-0797","article-title":"Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy","volume":"77","author":"Mahne","year":"2017","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zappasodi, R., Sirard, C., Li, Y.Y., Budhu, S., Abu-Akeel, M., Liu, C.L., Yang, X., Zhong, H., Newman, W., and Qi, J.J. (2019). Rational combination of GITR agonism with PD-1 blockade. Cancer Res., 79.","DOI":"10.1158\/1538-7445.SABCS18-2711"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Weber, R., Fleming, V., Hu, X.Y., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., and Umansky, V. (2018). Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01310"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2326-6066.CIR-19-0008","article-title":"TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma","volume":"7","author":"Holtzhausen","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mengos, A.E., Gastineau, D.A., and Gustafson, M.P. (2019). The CD14(+) HLA-DRlo\/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01147"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ramos, R.N., Piaggio, E., and Romano, E. (2017). Mechanisms of Resistance to Immune Checkpoint Antibodies. Handb. Exp. Pharm.","DOI":"10.1007\/164_2017_11"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol. Immun."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ribas, A., Robert, C., Hodi, F.S., Wolchok, J.D., Joshua, A.M., Hwu, W.J., Weber, J.S., Zarour, H.M., Kefford, R., and Loboda, A. (2015). Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J. Clin. Oncol., 33.","DOI":"10.1200\/jco.2015.33.15_suppl.3001"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Tarhini, A.A., Lin, Y., Lin, H.M., Vallabhaneni, P., Sander, C., LaFramboise, W., and Hamieh, L. (2017). Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. Oncoimmunology, 6.","DOI":"10.1080\/2162402X.2016.1231291"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Po\u017aniak, J., Nsengimana, J., Laye, J.P., O\u2019Shea, S.J., Diaz, J.M.S., Droop, A.P., Filia, A., Harland, M., Davies, J.R., and Mell, T. (2019). Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. Cancer Res.","DOI":"10.1158\/0008-5472.CAN-18-2864"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1\/Anti-CTLA-4 Combined Therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.it.2015.09.007","article-title":"Interferons and the Immunogenic Effects of Cancer Therapy","volume":"36","author":"Minn","year":"2015","journal-title":"Trend. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN gamma in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/gcc.22468","article-title":"Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors","volume":"56","author":"Budczies","year":"2017","journal-title":"Gene Chromosome Canc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., and Gajewski, T.F. (2013). Up-Regulation of PD-L1, IDO, and T-regs in the Melanoma Tumor Microenvironment Is Driven by CD8(+) T Cells. Sci. Transl. Med., 5.","DOI":"10.1126\/scitranslmed.3006504"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2019.01.006","article-title":"Clonal Deletion of Tumor-Specific T Cells by Interferon-gamma Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade","volume":"50","author":"Pai","year":"2019","journal-title":"Immunity"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"U231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Trujillo, J.A., Luke, J.J., Zha, Y.Y., Segal, J.P., Ritterhouse, L.L., Spranger, S., Matijevich, K., and Gajewski, T.F. (2019). Secondary resistance to immunotherapy associated with beta-catenin pathway activation or PTEN loss in metastatic melanoma. J. Immunother Cancer, 7.","DOI":"10.1186\/s40425-019-0780-0"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Roh, W., Chen, P.L., Reuben, A., Spencer, C.N., Prieto, P.A., Miller, J.P., Gopalakrishnan, V., Wang, F., Cooper, Z.A., and Reddy, S.M. (2017). Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aah3560"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fimmu.2013.00346","article-title":"Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function","volume":"4","author":"Ott","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Yang, L., Li, A.T., Lei, Q.Y., and Zhang, Y. (2019). Tumor-intrinsic signaling pathways: Key roles in the regulation of the immunosuppressive tumor microenvironment. J. Hematol. Oncol., 12.","DOI":"10.1186\/s13045-019-0804-8"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAF(V600E) Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/0008-5472.CAN-18-0365","article-title":"Oncogenic BRAF(V600E) Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis","volume":"78","author":"Shabaneh","year":"2018","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1158\/0008-5472.CAN-16-1755","article-title":"Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors","volume":"77","author":"Steinberg","year":"2017","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e1468955","DOI":"10.1080\/2162402X.2018.1468955","article-title":"Immunological effects of BRAF+MEK inhibition","volume":"7","author":"Ascierto","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI98689","article-title":"Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma","volume":"128","author":"Veatch","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2017.10.006","article-title":"Epigenetics of Malignant Melanoma","volume":"51","author":"Moran","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.7150\/thno.36218","article-title":"The \u201cART\u201d of Epigenetics in Melanoma: From Histone \u201cAlterations, to Resistance and Therapies\u201d","volume":"10","author":"Strub","year":"2020","journal-title":"Theranostics"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA methylation loss immune evasion of tumours with high mutation and copy number load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e96793","DOI":"10.1172\/jci.insight.96793","article-title":"CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients","volume":"3","author":"Goltz","year":"2018","journal-title":"JCI Insight."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: Past and future","volume":"10","author":"Sarkar","year":"2015","journal-title":"Epigenetics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","article-title":"Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy","volume":"40","author":"Emran","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R.E., Luoma, A., Tsoucas, D., Qiu, X., Lim, K., and Rao, P. (2018). A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science.","DOI":"10.1126\/science.aao1710"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Xiao, Q., Nobre, A., Pi\u00f1eiro, P., Berciano-Guerrero, M.-A., Alba, E., Cobo, M., Lauschke, V.M., and Barrag\u00e1n, I. (2020). Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010286"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"C569","DOI":"10.1152\/ajpcell.00207.2015","article-title":"Hypoxia: A key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia","volume":"309","author":"Noman","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Daniel, S.K., Sullivan, K.M., Labadie, K.P., and Pillarisetty, V.G. (2019). Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clin. Transl. Med., 8.","DOI":"10.1186\/s40169-019-0226-9"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biol. Sex Differ."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-019-02318-8","article-title":"Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition","volume":"68","author":"Chat","year":"2019","journal-title":"Cancer Immunol. Immun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2019.06.013","article-title":"Germinal immunogenetics as a predictive factor for immunotherapy","volume":"141","author":"Refae","year":"2019","journal-title":"Crit. Rev. Oncol. Hemat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s10038-018-0468-1","article-title":"The era of immunogenomics\/immunopharmacogenomics","volume":"63","author":"Zewde","year":"2018","journal-title":"J. Hum. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Sender, R., Fuchs, S., and Milo, R. (2016). Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol., 14.","DOI":"10.1101\/036103"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.12938\/bmfh.19-023","article-title":"Interaction of the microbiota with the human body in health and diseases","volume":"39","author":"Altves","year":"2020","journal-title":"Biosci. Microb. Food Health"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cytogfr.2017.06.002","article-title":"Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer","volume":"36","author":"Bellone","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Piro, G., Carbone, C., Carbognin, L., Pilotto, S., Ciccarese, C., Iacovelli, R., Milella, M., Bria, E., and Tortora, G. (2019). Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. Cancers, 11.","DOI":"10.3390\/cancers11101525"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Peng, W.Y., Chen, J.Q., Liu, C.W., Malu, S., Creasy, C., Tetzlaff, M., Xu, C.Y., McKenzie, J., Zhang, C.L., and Liang, X.X. (2016). Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Res., 76.","DOI":"10.1158\/1538-7445.AM2016-4363"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/4071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:36:17Z","timestamp":1760175377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/4071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":120,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21114071"],"URL":"https:\/\/doi.org\/10.3390\/ijms21114071","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]}}}